VANCOUVER, British Columbia, Sept. 11 /PRNewswire/ -- Enox Biopharma, Inc., a medical-device company, dedicated to the commercializing of a unique drug eluting technology for preventing microbial infections associated with certain medical devices, announced today that it will present full details of the successful development of the self-sterilizing urinary catheters at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which convenes in San Francisco, September 12-15. The world's largest convention of its kind, the ICAAC brings together more than 10,000 physicians, researchers and other healthcare professionals to foster worldwide solutions to the problem of infectious diseases.
At ICAAC, Dr. Gilly Regev-Shoshani, a UBC research associate working on this project, and Dr. Chris Miller, a UBC clinical assistant professor and a director of Enox, will present data outlining the Enox urinary catheter's ability to slowly release nitric oxide into a solution over the course of two weeks. The result: a self-sterilizing process, which prevents biofilm formation on the catheter, inhibits bacterial growth in the area immediately surrounding the catheter without lingering within the body. Nitric oxide exhibits strong activity against a wide range of pathogens and is part of the body's innate response to infections. Enox's innovative approach addressing hospital acquired infections offers significant advantages over other antiseptic coating or drug eluting technologies. Nitric oxide releasing catheters are less toxic to the human body; they remain effective over a longer period of time; and they present limited risk, if any, to developing antibiotic resistance to various bacterial strains.
Enox's First Product, a Self-Sterilizing Urinary Catheter
A team lead by Professor Yossef Av-Gay , of the Faculty of Medicine, University of British Columbia and the Founder and CEO of Enox, has developed a patented, self-sterilizing catheter that, in a controlled process, slowly releases small amounts of nitric oxide gas molecules. Nitric oxide prevents biofilm formation and bacterial growth, addressing a growing concern: catheter-associated urinary infection which is the most common hospital acquired infection, affecting over one million people annually in the U.S. alone.
Hospital acquired infections are critically interconnected with the increasing threat of antimicrobial resistance. They are frequently caused by bacteria that have become resistant to multiple antibiotics. More than half of these infections are attributed to the use of in-dwelling medical devices such as urinary catheters. Hospital acquired infections can be formed when bacteria attach themselves to medical devices, including urinary catheters, forming microbial biofilms that are particularly adept at developing drug resistance. With the heightened attention to this problem, medical professionals have been developing various strategies to lower the rates of infections without being compelled to reduce the number of devices used.
Safe Harbor Statement
This press release contains certain forward-looking statements. Forward-looking statements may include our statements regarding our goals, beliefs, strategies, objectives, plans, including product and service developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Further information on potential factors that could affect our business is described under the heading "Risks Related to Our Business" in Part I, Item 1, "Description of Business" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in our registration statement on Form S-1 no. 333-154763, which was declared effective on October 31, 2008. Except as otherwise required by law, Enox Biopharma, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact: Enox Biopharma, Inc. +1 (604) 637-9744 firstname.lastname@example.org
|SOURCE Enox Biopharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved